Hydromorphone controlled release - DURECT Corporation

Drug Profile

Hydromorphone controlled release - DURECT Corporation

Alternative Names: ORADUR-Hydromorphone; PTI 202

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator DURECT Corporation
  • Developer Pain Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 13 Jul 2017 Hydromorphone controlled release is still in phase I trials for Pain in USA (DURECT Corporation pipeline, July 2017)
  • 01 Dec 2016 Pain Therapeutics returns development and commercialisation rights for Hydromorphone controlled release to DURECT Corporation
  • 07 Aug 2014 Phase-I clinical trials in Pain (Abuse-resistant) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top